Trial Profile
480 Study: Phase 2b Open-label, Randomized Study in Treatment Naive Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron Plus Ribavirin Given Bi-Weekly to PEG-Intron Plus Ribavirin Given Weekly.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms EMPOWER
- Sponsors Biolex
- 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2010 Tolerability results from EMPOWER have been presented as a late-breaker at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD).
- 02 Nov 2010 Results reported at AASLD, according to a OctoPlus media release.